Please login to the form below

Not currently logged in
Email:
Password:

ofatumumab

This page shows the latest ofatumumab news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

The verdict is based on data from the RESONATE trials and a three-year follow-up study, one of which showed that in comparison with GlaxoSmithKline's Arzerra (ofatumumab), the BTK

Latest news

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    The drug is facing patent expiry in 2019, however, so with siponimod Novartis has a means of extending its franchise - which also includes recently-acquired CD20-targeteing drug Arzerra (ofatumumab) - once

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    Particular attention is given in its presentations to two new candidates - multiple sclerosis candidate OMB157 (ofatumumab) and QAW039 (fevipiprant) for asthma.

  • Novartis buys rights to GSK's Arzerra in MS for $1bn Novartis buys rights to GSK's Arzerra in MS for $1bn

    GlaxoSmithKline has sold rights to use its ofatumumab antibody in autoimmune diseases to Novartis in a $1bn agreement. ... Novartis will pay $300m upfront to Glaxo for ofatumumab, followed by another $200m after the start of late-stage clinical trials of

  • Imbruvica shines in combination trial Imbruvica shines in combination trial

    An earlier trial of the drug as a single-agent therapy in CLL indicated it was more effective than GlaxoSmithKline (GSK) and Genmab's Arzerra (ofatumumab).

  • England's Cancer Drugs Fund: Fixing a broken system England's Cancer Drugs Fund: Fixing a broken system

    GlaxoSmithKline has been the hardest hit in terms of drugs, given that three of its treatments: breast cancer medicine Tyverb (lapatinib), leukaemia drug Arzerra (ofatumumab) and non-adipocytic soft tissue sarcoma ... GlaxoSmithKline's Tyverb (lapatinib):

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Option to acquire. 1250. GSK. Novartis. Arzerra [ofatumumab] anti CD20 monoclonal antibody in oncology indications.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics